These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18722559)

  • 1. Altered B-cell signaling in lupus.
    Liu K; Mohan C
    Autoimmun Rev; 2009 Jan; 8(3):214-8. PubMed ID: 18722559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [B-cell anomalies in systemic lupus erythematosus].
    Tron F; Jacquot S; Gilbert D
    Ann Med Interne (Paris); 2002 Dec; 153(8):503-12. PubMed ID: 12610424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex and systemic lupus erythematosus: the role of the sex hormones estrogen and prolactin on the regulation of autoreactive B cells.
    Grimaldi CM
    Curr Opin Rheumatol; 2006 Sep; 18(5):456-61. PubMed ID: 16896282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic basis of murine lupus.
    Santiago-Raber ML; Laporte C; Reininger L; Izui S
    Autoimmun Rev; 2004 Jan; 3(1):33-9. PubMed ID: 14871647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunctional B cells in systemic lupus erythematosus.
    Renaudineau Y; Pers JO; Bendaoud B; Jamin C; Youinou P
    Autoimmun Rev; 2004 Nov; 3(7-8):516-23. PubMed ID: 15546800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis.
    Shi X; Xie C; Chang S; Zhou XJ; Tedder T; Mohan C
    Arthritis Rheum; 2007 Sep; 56(9):3057-69. PubMed ID: 17763445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B lymphocyte selection and survival in systemic lupus.
    Liossis SN; Zouali M
    Int Arch Allergy Immunol; 2004 Jan; 133(1):72-83. PubMed ID: 14726634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding.
    Nitschke L; Lajaunias F; Moll T; Ho L; Martinez-Soria E; Kikuchi S; Santiago-Raber ML; Dix C; Parkhouse RM; Izui S
    Int Immunol; 2006 Jan; 18(1):59-68. PubMed ID: 16291654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell biology and dysfunction in SLE.
    Anolik JH
    Bull NYU Hosp Jt Dis; 2007; 65(3):182-6. PubMed ID: 17922667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between systemic lupus erythematosus and deficiencies of the complement system.
    Goerg S
    Cell Mol Biol (Noisy-le-grand); 2002 May; 48(3):237-45. PubMed ID: 12030427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies.
    Lee HJ; Sinha AA
    Autoimmunity; 2006 Sep; 39(6):433-44. PubMed ID: 17060022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics.
    Tao J; Dong J; Li Y; Liu YQ; Yang J; Wu Y; Li L; Shen GX; Tan ZJ; Tu YT
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):433-7. PubMed ID: 19335730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease.
    Fairhurst AM; Wandstrat AE; Wakeland EK
    Adv Immunol; 2006; 92():1-69. PubMed ID: 17145301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory and pathogenetic mechanisms of autoantibodies in SLE.
    Radic M; Herrmann M; van der Vlag J; Rekvig OP
    Autoimmunity; 2011 Aug; 44(5):349-56. PubMed ID: 21231891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered T and B lymphocyte signaling pathways in lupus.
    Peng SL
    Autoimmun Rev; 2009 Jan; 8(3):179-83. PubMed ID: 18721908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?
    Binard A; Le Pottier L; Saraux A; Devauchelle-Pensec V; Pers JO; Youinou P
    J Autoimmun; 2008; 30(1-2):63-7. PubMed ID: 18155417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms.
    Barrat FJ; Meeker T; Chan JH; Guiducci C; Coffman RL
    Eur J Immunol; 2007 Dec; 37(12):3582-6. PubMed ID: 18034431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant HS1 molecule in a patient with systemic lupus erythematosus.
    Sawabe T; Horiuchi T; Koga R; Tsukamoto H; Kojima T; Harashima S; Kikuchi Y; Otsuka J; Mitoma H; Yoshizawa S; Niho Y; Watanabe T
    Genes Immun; 2003 Mar; 4(2):122-31. PubMed ID: 12618860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta-like 1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice.
    Moriyama Y; Sekine C; Koyanagi A; Koyama N; Ogata H; Chiba S; Hirose S; Okumura K; Yagita H
    Int Immunol; 2008 Jun; 20(6):763-73. PubMed ID: 18381350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutics for systemic lupus erythematosus.
    Wiesendanger M; Stanevsky A; Kovsky S; Diamond B
    Curr Opin Rheumatol; 2006 May; 18(3):227-35. PubMed ID: 16582684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.